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Abstract
Post-traumatic stress disorder (PTSD) is a chronic and disabling anxiety disorder
associated with a traumatic event [1]. It is linked to increased risk of suicide and
deficits in social functioning [2, 3]. Despite extensive study in psychiatry, the
underlying mechanisms of PTSD are still poorly understood [4, 5]. Currently, the
diagnosis for PTSD is based on clinical observation and symptom checklist [4, 6-8]
and no laboratory blood-based tests. Although biomarker discovery for PTSD is not
easy [8], a reliable biomarker would significantly impact the diagnosis and therapeutic
monitoring of PTSD. Developing interventions to identify and treat PTSD requires
objective approaches to determining the presence of PTSD [8]. Substantial data
indicate several potential biomarkers for PTSD. Of these candidate markers, p11
(S100A10) has been studied in PTSD animal models [7] and in human subjects with
PTSD [6]. We found that p11 is over-expressed in both animal models and post-
mortem brains of subjects with PTSD [7]. Incorporating testing of p11, a novel
biomarker for PTSD, into clinical practice, along with more subjective measures, such
as participants’ medical history, mental status, duration of symptoms, and symptom
checklist or self-report, would provide additional power to predict impending PTSD.
In this chapter, we discuss the biomarker concept and the potential clinical utility of
PTSD biomarkers. We further discuss the potential of p11 as a PTSD biomarker and
as a tool that may enhance PTSD diagnosis and intervention in health care practice.
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1. Introduction
Post-traumatic stress disorder (PTSD) is a chronic and disabling anxiety disorder which is a
result of exposure to a traumatic event and is associated with an increased risk of suicide and
marked deficits in social dysfunction [2, 3]. Currently, a PTSD diagnosis is made based on
clinical observation, symptoms, and the duration of symptoms. In 2013, the American
Psychiatric Association’s Fifth Edition of the Diagnostic and Statistical Manual of Mental Disor‐
ders (DSM-5) revised PTSD diagnostic criteria to better codify it to adults, adolescents, and
children over age six. The criteria currently include exposure to a traumatic event and
symptoms of four symptom clusters: intrusion, avoidance, negative alterations in cognitions
and mood, and alterations in arousal and reactivity. Additional criteria include the duration
of symptoms [9]. Given that there are currently no laboratory biomarker tests for PTSD, this
chapter will discuss the concept of using biomarkers to diagnose the potential for the existence
of PTSD. Specific focus will be given to the potential of biomarker p11.
2. Biomarker concept
Biomarkers are defined as “cellular, biochemical, or molecular alterations that are measurable
in biological media such as human tissues, cells, or fluids” [10-12]. Biomarkers can be meas‐
urable and quantifiable biological parameters, such as levels of protein or enzyme and
hormone in the cerebrospinal fluid, saliva and blood, or mRNA specimen levels [10-12]. Those
markers may be related to health and physiological conditions, metabolic processes, disease
risk, psychiatric disorders, and environmental exposure, as well as disease diagnosis [13].
Biological changes, which link mechanism of drug action to clinical effectiveness, are also
considered biomarkers [14]. Therefore, biomarkers may be considered as any substance,
structure of molecule, or biological process that are measurable, influential and/or able to
predict the incidence of outcome of disease (WHO International Program on Chemical Safety).
3. Biomarker classification and application
Biomarker research has advanced substantially as part of the Human Genome Project [15].
Initially, potential gene biomarkers were screened using high-throughput analytical instru‐
ments. Those markers were classified into four subgroups: type 0 biomarkers; type 1 biomark‐
ers; surrogate end point-type (type 2 biomarkers); and risk markers (http://en.wikipedia.org/
wiki/Human_Genome_Project). Depending on the function of those markers, they may be
called imaging biomarkers (CT, PET, MRI), molecular biomarkers, or genetic markers.
Molecular biomarkers include the markers in biological specimens (plasma, serum, saliva,
cerebrospinal fluid, bronchoalveolar lavage, and biopsy). They can be peptides, proteins, lipids
metabolites, enzymes, and other small molecules (http://en.wikipedia.org/wiki/
Human_Genome_Project). Genetic markers are micromRNA, mRNA and DNA mutations, or
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polymorphisms. Finally, these markers may also be used for diagnosing the disease, deter‐
mining the stage of the disease, monitoring the outcome of the treatment, and evaluating the
disease prognosis.
4. Potential PTSD biomarkers
For the last 10 years, researchers have been focusing on developing a single test, such as a
blood or genetic test, which may determine PTSD and simplify its treatment. In other medical
fields, biomarkers have already been developed and used for diagnosis. For example, choles‐
terol measurements and genetic tests have been used for predicting the risks for heart attacks
and Huntington’s disease, respectively. In psychiatry, researchers hope to use the same
strategies to identify and implement the biomarkers for predicting PTSD risk(s). However, the
searching for such a test is still ongoing, though scientists are closer than ever to achieve this
goal. Why is the search for biomarkers for PTSD needed when the disorder has been diagnosed
by clinical-interview-based DSM diagnostic criteria for decades. Because, at least in part,
biomarkers can help us better understand PTSD, its etiology and its pathologies, which in turn
can lead to the development of more successful therapeutic approaches. It may help psychia‐
trists make faster and more effective decisions on the treatments based on the individual’s
pathology. In addition, biomarkers might identify high-risk populations that had not mani‐
fested any symptoms met in PTSD diagnostic criteria. To search for PTSD biomarkers, high-
throughput omic approaches are required. The approaches used in biomarker studies of other
diseases [16, 17] have just begun to be used in PTSD research. Although potential biomarker(s)
for PTSD have been reported in the animal research [8] and human subjects research [6], the
confirmation and validation of their clinical utility have not been accomplished. In PTSD
biomarker studies, gene expression, metabolite levels and protein concentration in saliva [18],
blood [19], cerebral spinal cord fluid [20], urine [21], and tissues [7] are compared between
PTSD patients and healthy control subjects. In addition, physiological parameters (blood
pressure [22], ECG [23], heartbeat [24], neurotransmitters [25-27], and brain imaging [28] are
considered as biomarkers for PTSD.
PTSD biomarkers can be associated with PTSD-related behavioral characteristics (e.g., hyper-
vigilance), the level or type of exposure to traumatic stress, genetic susceptibility, conditions
of response to traumatic stress exposure, subclinical or clinical state, and conditions of response
to therapy. During the course of PTSD, or after single or multiple traumatic stresses, the
biomarkers can be identified. It also can be a predictor for PTSD-related risk, state, or pro‐
gression. Like biomarkers identified in cancer research, PTSD biomarker research may be used
for antecedent, screening, diagnostic, monitoring stage, and prognosis. One biomarker may
be associated with a single or multiple phenotypes of PTSD, while a single symptom can be
associated with multiple PTSD biomarkers.
Few studies have evaluated the use of multiple biomarkers for patients' risk stratification [29].
The desirable properties of biomarkers for PTSD vary with their different usages. For example,
a screening test requires having high sensitivity, specificity, predictive values, large likelihood
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ratios, and low cost to test a large population including normal and high-risk subjects. A
diagnostic biomarker may be chosen for testing stages of the disease (acute and chronic). In
those tests, sensitivity or specificity of monitoring biomarkers are less important because the
marker from the same individual serves as his or her own control. The ability to monitor intra-
individual variation is more important. Costs may be less important for prognostic markers
since only those diagnosed with PTSD are subjects of focus.
In PTSD biomarker research, the sample size is often critical. A standard diagnostic biomarker
test requires a relatively smaller sample size and a cross-sectional design. However, PTSD
biomarker research requires a larger sample size and a prospective design. Although all
biomarker features can be shown in one biomarker, a specific biomarker feature for use is the
ultimate goal in the search for PTSD biomarkers. It would be ideal to have all the features to
test PTSD and to help clinicians optimally manage PTSD patients with specific therapeutic
targets. For example, the level of glucocorticoid [30] and/or concentration of epinephrine in
the blood could be an indicator of responding to traumatic stress, or a plasma GABA level may
evaluate whether or not the subject is recovering from trauma [31]. It is important that a
biomarker test is an accurate, reproducible, standardized and acceptable procedure for PTSD
diagnosis.
4.1. A strategy to identify a PTSD biomarker
The development of PTSD biomarker(s) for clinical utility is a process from preclinical
development (potential biomarker identification) to clinical validation (clinical utility appro‐
val) [8]. This long process includes three major steps: screening, analytical validation, and
clinical validation. In the initial stage of screening, the high-throughput approaches are used
to search for the potential biomarker(s). Analytical validation is laboratory or bench work,
which involves sample selection, collection, storage, and determination of the optimum
analytical procedure that provide high reproducibility and accuracy. Clinical validation
(clinical utility) is the final step of the development of an accurate biomarker test, including
testing sensitivity and specificity of the diagnosis [8].
4.2. Screening biomarker(s) for PTSD
Biomarker screening is the first step in identifying a potential PTSD biomarker. During the
screening stage, researchers can start the study from animal models or human subjects. In
general, animal models needs to be validated [29]. If human subjects are used, the bias should
be avoided in the sample selection process. Since current animal models of PTSD have used
different stress paradigms, a wide range of behavioral responses is obtained. In many prior
studies, the data are presented by the mean values (with the standard deviation or the standard
error) of the entire study group. It is known that only a proportion of individuals (20%–30%)
who are exposed to a traumatic event will eventually develop PTSD [29]. Therefore, it is key
to identify a marker for those subjects who are in the risk population to provide a solid basis
for biomarker validation research [29].
Unlike the research in other medical fields, PTSD biomarker study provides little information
about the molecular mechanisms of post-traumatic psychopathology. Previously, a genome-
wide screen in a validated animal model showed the possible biomarkers for PTSD [29]. A
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genomic analysis requires pure samples, which are identified by highly stringent criteria. The
subjects are validated along three dimensions—analogous (similarity of phonotype), predic‐
tive (predictability of drug response or stress), and biological mechanism (regulation of gene
expression and brain function). Once a potential biomarker is identified in the screening stage,
an analytical validation is considered.
4.3. Analytical validation of the PTSD biomarker assay
A standardized biomarker validation process used in oncology has been considered for use in
PTSD biomarker research. Adaptation of this methodological approach includes a rigorous
definition and evaluation of the whole process of PTSD biomarker determination (analytical
validation), and an assessment of the impact of PTSD biomarker on clinical practices (clinical
validation).
Here, we briefly discuss three of the several terms that relate to analytical validation of the
biomarker assay for PTSD. The first term is precision, which relates to reproducibility in that
others should obtain similar results when following the original protocol procedures [32, 33].
Precision includes repeatability, intermediate precision, and reproducibility. Repeatability
indicates the levels of the precision under the same operating conditions over a short interval
of time and is referred to as intra-assay precision. Intermediate precision is within laboratory
variations (different days, analysts, equipment, etc.). The second term is accuracy, which
relates to the closeness of agreement between the value that is accepted either as a conventional
true value or an accepted reference value(http://www.fda.gov/downloads/Drugs/Guidance‐
ComplianceRegulatoryInformation/Guidances/ucm073381.pdf). The third term is detection
limit, which refers to the lowest quantity of a substance relative to a blank value within a stated
confidence limit (generally 1%) (http://en.wikipedia.org/wiki/Detection_limit). A signal-to-
noise ratio between 3:1 to 2:1 is generally acceptable for estimating the detection limit (http://
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
ucm073381.pdf).
There are four major phases in the analytical validation stage, including setting up and
standardizing operating procedures, and obtaining an internal quality control and external
quality assessment. In phase one, operating procedures are established for PTSD biomarker
determination. Phase two entails the validation of the operating procedures in terms of
precision and accuracy according to the standards definition of operating procedures. Phase
three obtains an internal quality control by evaluation of the validated standards within the
laboratory. The final phase of the analytical validation is to conduct an external quality
assessment comparison and assessment of their accuracy between laboratories.
In summary, analytical validation is to examine whether the procedure is suitable for testing
PTSD. The analytical procedures in the protocol should be clearly defined. Thus, analytical
validation should be done in different testing sites (Lab) using the same protocol. Validation
includes the biomarkers’ specificity, linearity, accuracy, precision (repeatability, intermediate
precision, and reproducibility), range quantitation limit, and detection limit. Analytical
validations must be completed prior to their use in clinical sites. In 1999, the United States Food
and Drug Administration established final guidelines for the industry validation of analytical
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procedures and terminology (http://www.fda.gov/downloads/Drugs/GuidanceComplian‐
ceRegulatoryInformation/Guidances/ucm073381.pdf) [32, 33], which provides guidance on
the validation of analytical procedures.
In the screening stage, high-throughput approaches, such as gene microarray and proteomics,
are the important formats for simultaneous analyses of tens of thousands of molecules in a
sample. These approaches require quality control and quality assurance. Many factors,
including changes in the reaction conditions and calibration, influence the results in the
analytical phase. Furthermore, since high-throughput approaches use many reagents or
samples together in a single device, it makes the process more complex. Therefore, it is
important to control analytical factors at different strategies by replicating analysis and
normalization. The data with analytical validation for each operator and instrument can be
provided to the next step, clinical validation.
4.4. Clinical validation of the PTSD biomarker assay
The development of a new PTSD biomarker test terminates with clinical validation that
includes five phases: preclinical exploratory, clinical assay and validation, retrospective
longitudinal, prospective screening, and PTSD control. Preclinical exploratory involves using
a case-control approach to identify promising PTSD biomarker candidates. The second phase
of clinical validation is to determine if a clinical biomarker assay can detect PTSD (population-
based). The third phase uses a nested case-control approach in a population cohort; retrospec‐
tive longitudinal study is conducted to verify if the biomarker is able to detect PTSD before it
clinically manifests. In phase four, prospective screening is performed to determine the extent
and characteristics of PTSD detected by tests in the subjects of cross-sectional cohort. Finally,
if feasible, a randomized trial is conducted to examine the effect of test screening on reducing
the burden of PTSD.
Clinical validation entails testing the ability of the markers to distinguish PTSD from non-
PTSD cases, and to test the sensitivity and specificity. In this stage, it needs to find the true-
positive rate (TPR), the proportion of PTSD cases who are biomarker-positive; the false-
positive rate (FPR), and the proportion of non-PTSD subjects who are biomarker-positive.
Then, a receiver operating characteristic (ROC) curve should be plotted. In this plot, the TPR
versus the FPR can be used as the discrimination threshold. During clinical validation, it is
important to assess factors associated with the biomarker, including demographic details such
as age, gender, and race.
Clinical validation of PTSD biomarkers should include both retrospective and prospective
analyses. Using stored samples, a retrospective analysis can be used to determine the detective
ability of the potential biomarker(s) and the cut-point. If it involves multiple potential PTSD
biomarkers, those PTSD markers can be compared and developed to algorithms together.
Longitudinal observation will examine the variability within-subjects and compare the time-
specific ROC. Again, the cut-off for a biomarker is determined by a ROC curve.
Longitudinal observation provides data from the sequential testing point, which may add
additional power to the PTSD biomarker. The key issue is how to obtain the appropriate and
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well-characterized samples from each collecting point. Sometimes the subjects cannot be
identified again or have dropped out from the study. In addition, we found that PTSD
biomarkers in the brain and in the blood are not necessarily altered in the same direction.
Therefore, determining the relationship between biomarkers in the peripheral nervous system
and central nervous system could be more important in the clinical validation study for PTSD,
though sometimes those study designs are a challenge. Finally, clinical validity of PTSD
biomarker test, including its rates of false negatives and false positives, should be well
established before the tests enter clinical use. Meanwhile, bridging studies are required if
changes of platform device occurred after clinical validation.
5. P11 as a potential PTSD biomarker
Given that current diagnosis for PTSD rely on a clinician-administered interview, the devel‐
opment of a biomarker test for PTSD would be useful [7, 8]. There are no available laboratory
blood biomarker tests for PTSD. We have pioneered the use of our patented blood p11 mRNA
as a biomarker to differentiate PTSD from control and from other mental disorders. Our
previous study demonstrates that p11 mRNA levels can be differentially detected in human
blood from subjects with or without PTSD [7]. We, and others, found that p11 mRNA expres‐
sion is significantly changed in post-mortem cortex of patients with PTSD [7] and depression
[34]. That suggests that p11 mRNA levels in the peripheral blood cells can serve as a biomarker
for PTSD.
P11, annexin light chain [35], is a member of the S100 protein family. It is one of the proteins
within the EF-hand super-family of Ca2+ binding proteins [36]. The p11 gene is located in
chromosome 1q21 in humans and expressed in many types of cells and tissues, such as in the
lungs, intestines, kidneys, brain, and blood of many species [37]. P11 protein was originally
identified in a complex with the Ca2+/lipid-binding protein annexin A2 [36]. It regulated the
function of exocytosis and endocytosis. Unlike other S100 proteins, it has crucial amino acid
substitutions and deletions in the two EF-hand loops that render both Ca2+-binding sites
inactive [36, 37]. It is locked in the equivalent of a Ca2+-loaded structure and in a permanently
activated state. P11 binds to the target protein on hydrophobic cellular surfaces without Ca2+.
Thus, p11 regulates the function of several membrane proteins, such as annexin II and the 5-
HT1B receptor, which are associated with mental disorders [34]. In the nucleus, p11 participates
in the regulation of the stress response. P11 is up-regulated by stress or stress hormones in the
brain [7]. Stress-induced p11 overexpression is mediated by the glucocorticoid receptor (GR),
which interacts with glucocorticoid receptor response elements (GREs) in the p11 promoter
region [7]. These observations have received support from our data showing that mRNA levels
of p11 increased in the post-mortem prefrontal cortex (area 46) of PTSD patients. Furthermore,
in rats we showed that three days of inescapable shock induced over expression of p11 mRNA
in the prefrontal cortex (PFC) and elevated corticosterone levels in the plasma [7]. This up-
regulation of p11 expression can be countered by either a glucocorticoid receptor antagonist,
RU486, or by mutating two of the three GREs (GRE2 and GRE3) [7]. Our preliminary data (Fig.
1, unpublished data) also demonstrated that p11 was significantly over-expressed in the blood
of soldiers with PTSD who were deployed, compared to deployed soldiers who did not have
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PTSD (Fig. 1a and 1b). Such overexpression is significantly associated with the severity of PTSD
symptoms (Fig. 1c). Our results warrant further exploration of p11 as a potential biomarker
for PTSD in a large sample size.
Figure 1. P11 mRNA and protein levels were significantly higher in subjects with PTSD (n=67) than that in the non-
PTSD controls (n=67), and the relationship between blood p11 levels and PTSD symptom severity (unpublished data).
(a) P11 mRNA level was significantly higher in subjects with PTSD than that in the non-PTSD controls (**p<0.01). (b)
P11 protein level was significantly higher in subjects with PTSD than that in the non-PTSD controls (***p<0.001). (c)
The relationship between blood p11 protein levels and PTSD checklist (PCL) score (p<0.0027).
6. Biorepository or biobank in biomarker study
To obtain a large quantity of good quality samples is a challenge. It requires developing a
standardized protocol for sample collection, storage, and quantitative control. A biobank will
provide such opportunity. A preliminary type of biobank, a biorepository can store biological
samples (usually human) for use in PTSD biomarker research. The biobank market is expand‐
ing with a significant increase in using human tissues, blood, and other biomaterials to do
biomarker research, and pharmaceutical and diagnostic tool development [38]. In 2008, there
were 270 million specimens in biobanks. Each year, about 20 million samples have been
collected for research, including biomarker studies [39], indicating worldwide changes in the
nature of biomedical research. In general, more and more biobanks have been established.
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They are established by multiple research centers, leading to an infrastructure of next-
generation research demand [40]. A typical example is the Psychiatric Genomics Consortium
(PGC) that is comprised of more than 80 institutions. The PGC has samples from more than
150,000 people; of which, 36,989 samples are from subjects with diagnosed schizophrenia [41].
Recently, using the PGC samples, researchers have spotted 108 genetic loci in the DNA
sequence of schizophrenia. The large PGC sample has also allowed for the development of an
algorithm to calculate a ‘risk score’ for each variant’s contribution to schizophrenia. PGC plans
to sequence 100,000 subject samples with mental illnesses in an effort to identify the meaningful
biomarker associations [41].
However, there are many issues for biobanks ahead, including ethical, legal, and social issues
pertaining to their existence, the fairness of collecting donations from vulnerable populations,
providing informed consent to donors, the logistics of data disclosure to participants, the right
to ownership of intellectual property, and the privacy and security of donors who participate
[39]. Nevertheless, biobanks will provide a great opportunity to researchers in the PTSD
biomarker study.
7. Our biorepository and biomarker study, including p11 research
Since 2009, we have collected blood and saliva samples from soldiers who were deployed to
Iraq and Afghanistan. To date, over 2,000 blood and 5,000 saliva samples have been collected.
This study was initiated at Fort Bragg in 2009 and expanded to multiple Army National Guard
units throughout California, Pennsylvania, and Guam in 2011. Biological samples and detailed
mental health data, using DSM driven surveys, were voluntarily collected from soldiers,
including ~500 before, during, and following a deployment to Iraq or Afghanistan, to allow
for a longitudinal assessment. The mental health surveys contained established self-report
inventories (e.g., PCL, GAD, and PHQ). Using our biorepository dataset to examine p11 as a
potential PTSD biomarker may help scientists discover why some people, particularly those
in the military, develop PTSD, depression, and suicidal behaviors while others do not.
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